Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.

Fifty-four patients with clinical evidence of residual colorectal adenocarcinoma following surgical removal of the primary tumor were treated with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside. The objective response rate in these patients was 17%. Bone marrow suppression was the major toxic effect. These data fail to show an advantage of this combination therapy over previously described chemotherapeutic regimens.